Lilly's Foundayo Prescriptions Modest in Early Weeks, Clouding Oral GLP-1 Thesis

What happened

Eli Lilly's new oral obesity drug Foundayo (orforglipron) generated 7,335 prescriptions in its fourth week on the U.S. market, a pace that analysts describe as modest relative to Novo Nordisk's oral Wegovy. This early signal comes as Lilly's Q1'26 results reveal a 13% consolidated price headwind, with volume growth of 65% partially offset by lower realized prices and one-time rebate adjustments. The oral pill was positioned to expand the GLP-1 market by attracting injection-averse patients, but the prescription data raises concerns that it may primarily switch patients from existing injectable therapies rather than drive new-to-class starts. With the Medicare GLP-1 Bridge program starting July 1 and Novo's oral semaglutide launch planned for 2026, net pricing pressure is likely to intensify. At 34x P/E, the stock already prices in sustained GLP-1 category expansion, but early Foundayo data suggests the oral route may not provide the hoped-for volume offset to eroding pricing.

Implication

While one month of prescription data is insufficient to draw firm conclusions, it introduces downside risk to our base case which assumes Foundayo drives incremental new-to-class starts. We maintain our WAIT rating and look for accelerating prescription trends post Medicare Bridge activation and before Novo's oral launch. If Foundayo fails to show clear incremental volume within the next 6-12 months, we would trim positions.

Thesis delta

The early modest Foundayo prescription data contradicts our base case assumption that oral GLP-1 would drive new-to-class starts without worsening price mix. If this trend continues, it would break our thesis and require a downward revision of growth expectations and intrinsic value. We now need evidence that Foundayo's uptake is additive, not cannibalistic, within the next 90 days.